Roth MKM Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $65
Portfolio Pulse from Benzinga Newsdesk
Roth MKM has initiated coverage on CG Oncology with a Buy rating and set a price target of $65.
August 27, 2024 | 10:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM has initiated coverage on CG Oncology with a Buy rating and a price target of $65, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $65 by Roth MKM suggests a positive sentiment towards CG Oncology's stock. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100